Leukemia and Lymphoma

Saturday, July 15, 2017

FDA panel recommends approval for gene-altering therapy


CANCER DIGEST – July 15, 2017 – A FDA advisory panel unanimously recommended approval of a gene-altering therapy for a deadly form of childhood leukemia. If given final approval, it would be the first such drug in a new class of therapy called CAR T-cell therapy.

Saturday, June 24, 2017

Promising new drug for relapsed AML


Image shows increasing white blood cells in leukemia
Illustration by Scientific Animations
Image used under Creative Commons license via
Wikipedia
CANCER DIGEST – June 24, 2017 – Researchers have found a drug that inhibits a particular mutation in a deadly form of acute myeloid leukemia (AML) with promise of producing longer survival.
The sub-type of AML has a mutation in a gene called FLT3, found in about 30 percent of patients’ leukemia cells. 

Wednesday, May 10, 2017

Reprogramming T cells on the fly to fight cancer

Dr. Matthias Stephan
CANCER DIGEST – May 10, 2017 – The idea of using the body’s own immune system to halt cancer has a long history of research approaches. One of the most promising in that vein over the last decade has been immunotherapy, and most recently the use of T cells engineered with chimeric antigen receptors or CAR T cells.

Monday, December 26, 2016

Herpes virus linked to most common childhood cancer


CANCER DIGEST – Dec. 26, 2016 – Newborns with a common virus in the herpes family may have an increased risk of developing acute lymphocytic leukemia (ALL), according to new research. The study suggests the risk is even greater in Hispanic children.

The new research led by Stephen Francis, PhD, assistant professor of epidemiology at the University of Nevada and University of California, San Francisco was published online in Blood, the Journal of the American Society of Hematology (ASH).

Sunday, November 13, 2016

People with genetic disorder linked to long life have increased death rate from a common cancer drug



CANCER DIGEST – Nov. 13, 2016 – Cancer patients with a genetic disorder that has been linked to long life, ironically may be twice as likely to die when treated with a common chemotherapy drug, a new analysis shows.

Led by George McDonald, MD a gastroenterology researcher at Fred Hutchinson Cancer Research Center in Seattle, researchers analyzed the records of 3500 marrow transplant patients over a ten-year period between 1991 and 2011. The records analyzed included people who had been treated with busulfan as part of a chemotherapy regimen prior to bone marrow transplantation for blood cancers like leukemia or lymphoma.

Saturday, September 17, 2016

Researchers hopeful for improved T cell therapy for non-Hodgkin lymphoma


Dr. Stan Riddell, is a senior researcher for the trial –
Fred Hutch file photo
CANCER DIGEST – Sept. 17, 2016 – In an early clinical trial designed to determine the optimal safe dose, researchers at the Fred Hutchinson Cancer Research Center in Seattle, WA have seen promising results for an anti-cancer immune cell engineered from the patient’s own immune system. 

The early results of the engineered T cell, called JCAR014  were from what is called a dose-finding trial in patients with non-Hodgkin lymphoma (NHL) published in the journal Science Translational Medicine.

Saturday, August 13, 2016

Venetoclax safe, shows promise for AML


CANCER DIGEST – Aug. 12, 2016 – In a small trial with 32 patients with acute myelogenous leukemia (AML) that no longer responded to chemotherapy, four patients treated with a new drug achieved a complete response, meaning no sign of cancer, and six had no cancer cells present, but continued to have signs of the cancer in their blood.

That is enough of a response to the drug Venclexta (venetoclax) to give researchers hope of adding a new approach to treating acute myelogenous leukemia, a particularly deadly type of blood cancer in which only about 27 percent survive five years after diagnosis.

Monday, April 11, 2016

New drug approved for chronic lymphocytic leukemia


CANCER DIGEST – April 11, 2016 – The FDA today approved a new drug for treatment of patients with a form of chronic lymphocytic leukemia (CLL).

The drug manufactured by AbbVie Inc. of North Chicago, Illinois, is called Venclexta (venetoclax) and is for the treatment of patients with CLL who have a genetic abnormality called 17p deletion and who have been treated with a least one prior therapy.

Saturday, March 19, 2016

New drug shows promise for drug resistant leukemia


A scanning electron 
microscope image 
from normal circulating 
human blood. – Wikipedia
CANCER DIGEST – March 19, 2016 – Researchers have developed a compound that shows promise for extending survival in patients with a drug-resistant form of leukemia.

Adult acute myeloid leukemia (AML) is a cancer of theblood and bone marrow that usually gets worse quickly if it is not treated. It has a poor prognosis, with survival rates between 60 percent and 70 percent in children and less than 50 percent in adults.

Tuesday, February 16, 2016

Genetically modified immunotherapy shows ‘unprecedented’ success


Scanning electron micrograph
of a human T cell Credit: NIAID
CANCER DIGEST – Feb. 16, 2016 – Immune system cells engineered to attack cancer cells raised optimistic “alerts” in the mainstream media this week, as a researcher reported 94 percent of patients with advanced acute lymphoblastic leukemia (ALL) saw their symptoms disappear.

The results were reported at the just concluded American Association for the Advancement of Science conference in Washington, DC, by Dr. Stan Ridell, of Fred Hutchinson Cancer Research Center in Seattle, WA.

Saturday, November 7, 2015

Girl undergoes first-ever ‘gene-editing’ treatment


Layla, shown here at 16 months,
is the first patient to receive new
treatment 
CANCER DIGEST – Nov. 7, 2015 – A one-year-old girl in London, England with leukemia is now cancer free and doing well as a result of a new treatment that uses ‘molecular scissors’ to edit genes and create designer immune cells.

The girl, named Layla, had relapsed acute lymphoblastic leukemia (ALL) that had failed to respond to conventional therapies and had limited treatment options available.

The patient’s parents were keen to try the treatment. Mother, Lisa, says: "We didn’t want to accept palliative care and so we asked the doctors to try anything for our daughter, even if it hadn’t been tried before."

Wednesday, October 7, 2015

Imperfect match may be just as good as perfect match for blood cancers


scanning electron 
microscope image 
from normal circulating 
human blood. – Wikipedia
CANCER DIGEST – Oct. 7, 2015 – Using a half-matched donor bone marrow transplant may be just as good as a full match for treating blood cancers like leukemia and lymphomas, new research shows.

In the first study to compare the gold standard full-match to a half-match transplant using an identical protocol, researchers at the Thomas Jefferson Kimmel Cancer Center have shown three years after transplant approximately 70 percent of the patients in both groups were still alive and cancer free.

Sunday, September 27, 2015

New hope for older Hodgkin lymphoma patients


They lymph node system
throughout the body is part
of the immune system.
CANCER DIGEST – Sept. 27, 2015 – A new engineered antibody drug may offer hope for people over 60 with Hodgkin lymphoma, early results from a clinical trial show.

In the small trial of 27 people whose average age was 78 with Hodgkin lymphoma,  and were not able or willing to undergo standard chemotherapy, 24 achieved an objective response, meaning the drug halted the progression of the cancer or caused it to go into remission.

Monday, July 20, 2015

T-cell therapy slows plasma cancer


The micrograph shows abundant
cancerous plasma cells. – by Nephron
via Wikimedia
CANCER DIGEST – July 20, 2015 – Results from a clinical trial testing a new therapy for multiple myeloma  demonstrated a clinical response in 80 percent of patients with advanced disease who had undergone a stem cell transplants. A clinical response indicates a therapeutic effect for the treatment that uses a person's own immune system to recognize and destroy cancer cells.

Tuesday, June 30, 2015

Experimental combination treatment halts rare leukemia


prolymphocyte is a white
blood cell
 – Wikipedia

CANCER DIGEST – June 30, 2015 –An experimental new treatment approach for a rare, deadly leukemia can send the disease into remission even in patients for whom the standard therapy has failed, buying them more time to have the stem cell transplant that could save their lives, a small pilot study has found.

The new approach to battling T-cell prolymphocytic leukemia uses a combination of two drugs already approved for cancer and other therapies, alemtuzumab and cladribine. 

Thursday, April 9, 2015

Tumor DNA in blood predicts recurrence of lymphoma


CANCER DIGEST – April 9, 2015 – Patients who have had the most common form of lymphoma might learn if their cancer has returned earlier with a blood test, researchers say.

In a study that followed 126 patients who achieved complete remission of their diffuse large B-cell lymphoma (DLBCL) for many years, researchers found that measuring blood levels of the tumor’s DNA enabled detection of microscopic disease before it could be seen on computerized tomography CT scans.

Thursday, December 4, 2014

Drug for rare form of leukemia given FDA nod


Amgen's blinatumomab allows T-cells to
attach to an immature B-cell and destroy it.
CANCER DIGEST – Dec. 4, 2014 – The FDA has approved Blincyto (blinatumomab) to treat patients with a rare type of leukemia, called Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL).

Precursor B-cell ALL is a rapidly growing type of leukemia in which the bone marrow makes too many immature B-cells that are not yet functional in the immune system. The National Cancer Institute estimates that 6,020 Americans will be diagnosed with this form of leukemia and 1,440 will die from it in 2014. The Philadelphia chromosome is an abnormality that sometimes occurs in the bone marrow cells of leukemia patients and is linked to chronic myelogenous leukemia (CML).

Wednesday, August 20, 2014

Leukemia drug may slow metastasis in skin, breast and other cancers


CANCER DIGEST – Aug. 20, 2014 – A drug used to treat leukemia may be useful in slowing or halting cancer spread in other cancers, a new study shows.

The drug, Dasatinib is a type of drug called a protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that act as chemical messengers to stimulate cancer cells to grow. 

Tuesday, July 8, 2014

AMGEN drug for ALL receives FDA’s breakthrough designation


AboutKidsHealth.ca video
CANCER DIGEST – July 8, 2014 – The FDA granted breakthrough therapy status to blinatumomab for the most common form of acute lymphoblastic leukemia (ALL). The cancer results from too many immature white blood cells in the blood and bone marrow. To get breakthrough designation, a drug must show preliminary clinical evidence indicating the drug may demonstrate substantial improvement over existing therapies. A total of 82 of 189 (43 percent) patients treated with blinatumomab achieved a complete remission or a partial hematological recovery. The results were presented at the 2014 ASCO Annual Meeting in June. Blinatumomab is an engineered antibody that directs T-cells in the immune system to attack cells that produce certain molecules found on the surface of the abnormal ALL white blood cells. Sean E. Harper, MD, executive vice president, Research and Development at Amgen, which makes the drug, said in a press release that the company is currently recruiting for a large clinical trial that will compare blinatumomab to standard chemotherapy, and plans to enroll 400 patients over the next two to three years.

Wednesday, May 28, 2014


Promising target for treating leukemia

Courtesy – Institute for Research in Immunology and
Cancer of Université de Montréal
CANCER DIGEST – May 28, 2014 – A group of researchers at the Institute for Research in Immunology and Cancer of Université de Montréal have identified a gene responsible for tumor progression in leukemia. The gene, known as Brg1, plays a key role in leukemia stem cells that are the root cause of the disease, and lead to treatment resistance and relapse. The researchers led by Julie Lessard say that when the gene is removed from the leukemic cells they no longer divide, thus effectively shutting down the disease progression. If drugs can be developed that block the drug, it might lead to effective treatment for leukemia and other cancers. Their study was published in the journal Blood.

Tuesday, May 27, 2014


Phase 2 results in CPXcitement for AML

YouTube courtesy Leukemia and
Lymphoma Society of Canada
CANCER DIGEST – May 27, 2014 – Results from a small phase 2 clinical trial of a new chemotherapy for acute myeloid leukemia (AML) were favorable enough that researchers at the Moffitt Cancer Center in Tampa, FL, are now recruiting for a larger comparison clinical trial to determine effectiveness. AML is an aggressive blood cancer with very low rates of treatment success. The new drug called CPX-351 “encapsulates” two chemotherapy drugs, cytarabine and daunorubici, in a lipid shell that maintains the effective ratio of the two drugs until delivery to the tumor. In the early trial of 126 newly diagnosed AML patients those who received CPX-351 and whose AML arose out of a previously diagnosed hematologic disorder, such as myelodysplastic syndrome, had higher rates of remission and survived longer, although the objective of the trial was to determine the safest, most effective dose, not survival. The phase 3 CPX-351 clinical trial is currently open and recruiting patients and is designed to measure survival. Those interested in learning more about study should contact Clinical Research Coordinator Nancy Hillgruber atNancy.Hillgruber@Moffitt.orgThe results from the phase 2 study appeared in the May 22, 2014 journal Blood. An accompanying editorial explains why researchers are optimistic about CPX-351.

Thursday, May 15, 2014


Mayo Clinic early trial uses measles virus to treat blood cancer

Mayo Clinic YouTube
CANCER DIGEST – May 15, 2015 – In a first in class clinical trial, Mayo Clinic researchers have demonstrated a new approach to treating blood cancer using an engineered dose of the measles virus.  Two patients in the early stage trial with multiple myeloma, a cancer of the plasma cells,  were given doses of the virus and both have responded with reductions of cancer in the bone marrow. One patient, a 49-year-old woman, experienced complete remission of myeloma and has been clear of the disease for over six months. The findings appear in the journal Mayo Clinic Proceedings

No comments:

Post a Comment